

# **Evaluation of Linked, Open Data Sources for Mining Adverse Drug Reaction Signals**



#### <u>Pantelis Natsiavas</u><sup>1,2</sup>, Nicos Maglaveras<sup>1,2</sup> and Vassilis Koutkias<sup>2</sup>

- <sup>1</sup> Lab of Computing, Medical Informatics and Biomedical Imaging Technologies, Department of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
- <sup>2</sup> Institute of Applied Biosciences, Centre for Research & Technology Hellas, Thermi, Thessaloniki, Greece <a href="mailto:pnatsiavas@certh.gr">pnatsiavas@certh.gr</a>






## Pharmacovigilance Signals: Definition

"... information that arises from one or multiple sources (including observations and experiments), which suggests a new potentially causal association <u>OR</u> a new aspect of a known association, between an intervention and an event ..."



## The Goal of this Work






# Linked Data Model Requirements


- Data richness
- Semantic richness
- Semantic normalization
- Scalability
- Up-to-date maintenance



## Linked Data Model: Overview



## Data Richness Evaluation Process





#### Model Evaluation via Reference Datasets

Dataset	Positive controls	Negative controls	Sum
Harpaz et al. <sup>1</sup>	62	75	137
Ryan et al. <sup>2</sup>	165	233	398
Coloma et al. <sup>3</sup>	44	45	89
Total	271	353	624

<sup>&</sup>lt;sup>3</sup> Coloma, P.M. et al.: A Reference Standard for Evaluation of Methods for Drug Safety Signal Detection Using Electronic Healthcare Record Databases. Drug Saf. 36, 13–23 (2012).



<sup>&</sup>lt;sup>1</sup> Harpaz et al.: A time-indexed reference standard of adverse drug reactions. Sci. Data. 1, (2014).

<sup>&</sup>lt;sup>2</sup> Ryan, P.B. et al.: Defining a Reference Set to Support Methodological Research in Drug Safety. Drug Saf. 36, 33–47 (2013).

#### Data Richness: Evaluation Results

#### Evaluation results for the three reference datasets

		SIDER	DrugBank	LinkedSPL	ClinicalTrials.gov
a ot	Sensitivity	0.774	0.129	0.483	0.322
1 <sup>st</sup>	Specificity	0.213	0.906	0.506	0.64
2 <sup>nd</sup>	Sensitivity	0.782	0.176	0.145	0.230
Ziia	Specificity	0.408	0.893	0.725	0.815
3 <sup>rd</sup>	Sensitivity	0.909	0.295	0.545	0.409
	Specificity	0.111	0.978	0.444	0.689



#### Semantic Richness: Evaluation Results

	Classes	Properties	External reference properties
SIDER	15	22	2
DrugBank	104	114	25
LinkedSPL	5	104	3
ClinicalTrials.gov	63	157	0
Totals	187	397	30




#### Semantic Normalization: Evaluation Results

		ıl number rugs	PharmGK references		Percentage
SIDER		1,593	1,593		100%
DrugBanl	ζ.	8,054	1,625		20.17%
LinkedSP	L	51,305	886		1.72%
	Total number of drugs	ATC references	Percentage of ATC references	Comm ATC codes	Linking percentage
SIDER	1,593	1,593	100%	1049	65.85%
DrugBank	8,054	1,739	21.59%		13.02%



#### Semantic Normalization: Evaluation Results





## Scalability: Evaluation Results

Average execution time (in seconds)

	1st query	2 <sup>nd</sup> query	3 <sup>rd</sup> query
SIDER	2.79	22.12	21.53
DrugBank	1.37	1.42	1.55
LinkedSPL	23.58	21.73	22.86
ClinicalTrials.gov	1.70	3.33	3.26



## Challenges and Future Work

- Semantic normalization and interlinking
- Semantic enrichment
- Maintenance
- Future work
  - Integrate the proposed model in unstructured data analysis focusing on ADRs
  - Expand the model to accommodate biological data



## Discussion





Pantelis Natsiavas

pnatsiavas@certh.gr